Personalisation of Aspirin Adjuvant Therapy in Patients with Colorectal Cancer

结直肠癌患者阿司匹林辅助治疗的个体化

• 批准号: nhmrc : GNT1138047
• 负责人: A/Pr Oliver Sieber
• 金额: $ 76.26万
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/personalisation-aspirin-adjuvant-colorectal-cancer/1348112
• 关键词: Personalisation; Aspirin; Adjuvant; Therapy; Patients

Aspirin use is associated with a reduced risk of bowel cancer recurrence. However, benefit appears limited to a subset of patients, and some individuals experience side effects. We will analyse tumour samples from patients participating in the ASCOLT clinical trial of aspirin to identify molecular features that can predict who will benefit from aspirin. Predictive biomarkers would be of substantial clinical utility for guiding treatment, minimising toxicity and improving disease outcomes.

阿司匹林的使用与降低肠癌复发的风险有关。然而，受益似乎仅限于一小部分患者，一些人会出现副作用。我们将分析参加阿司匹林ASCOLT临床试验的患者的肿瘤样本，以确定可以预测谁将受益于阿司匹林的分子特征。预测性生物标志物将在指导治疗、将毒性降至最低和改善疾病结果方面具有实质性的临床实用价值。